Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice

por Irina V. Kolyadina, Natalia R. Abidova, Arshak A. Akopyan, Galina V. Antonova, Oksana I. Arapova, Elvira A. Bobrova, Larisa V. Bolotina, Chulpan K. Valiakhmetova, Anna V. Vasilevskaya, Lyubov Y. Vladimirova, Mikhail V. Volkonskiy, Inna P. Ganshina, Irina E. Gudkova, Alexandr S. Dergunov, Irina V. Evstigneeva, Viktoria S. Egurenkova, Aleksei V. Emshanov, Lyudmila G. Zhukova, Elena V. Zueva, Elena V. Karabina, James J. Kolokolov, Svetlana V. Kuzmicheva, Olesya A. Kuchevskaya, Ivan A. Luev, Ksenia S. Maistrenko, Elena V. Markizova, Vasily V. Marfutov, Sergey P. Medvedev, Yulia I. Merzlikina, Tatyana A. Nersesova, Elena G. Ovchinnikova, Svetlana A. Orlova, Natalia Y. Samaneva, Olesya A. Stativko, Anna E. Storozhakova, Daniil L. Stroyakovskiy, Alexander V. Sultanbaev, Asiat I. Tekeeva, Natalia V. Fadeeva, Alina N. Fedorova, Oksana M. Shalaeva, Irina A. Shangina, Oksana N. Shirokova, Alisa R. Shumskikh, Mariam Z. Yakubova
Publicado 2021

Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?

por Eijiro Shimada, Makoto Endo, Yoshihiro Matsumoto, Kenji Tsuchihashi, Mamoru Ito, Hitoshi Kusaba, Akira Nabeshima, Tomoya Nawata, Akira Maekawa, Tomoya Matsunobu, Nokitaka Setsu, Toshifumi Fujiwara, Keiichiro Iida, Makoto Nakagawa, Takeshi Hirose, Masaya Kanahori, Ryunosuke Oyama, Taichi Isobe, Hiroshi Ariyama, Kenichi Kohashi, Hidetaka Yamamoto, Yoshinao Oda, Yukihide Iwamoto, Koichi Akashi, Eishi Baba, Yasuharu Nakashima
Publicado 2021

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective

por Yuan P, Xu B
Publicado 2021

The efficacy of the combination of eribulin and trastuzumab in advanced HER2-positive breast cancer: the results of Russian observational study

por Elena I. Kovalenko, Elena V. Artamonova, Elena V. Karabina, Irina I. Andreiashkina, Ekaterina A. Prokof’eva, Nataliia O. Popova, Elena A. Gaisina, Irina V. Evstigneeva, Mikhail V. Shaidorov, Larisa A. Zhiliaeva, Dmitrii M. Ponomarenko, Alfiia I. Khasanova, Guzel Z. Mukhametshina, Anton E. Koziakov, Liudmila V. Vorotilina, Anton Iu. Povyshev, Elena I. Simolina, Vasilii V. Marfutov, Dmitrii V. Kozlov, Irina R. Suslova, Valentina E. Shikina, Tatiana V. Karandeeva, Artem O. Shepel’, Liudmila V. Kramskaia, Denis A. Oskirko, Olga S. Frolova
Publicado 2020

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurr...

por Puhalla S, Wilks S, Brufsky AM, O'Shaughnessy J, Schwartzberg LS, Berrak E, Song J, Vahdat L
Publicado 2016

Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first e...

por Irina V. Kolyadina, Inna P. Ganshina, Svetlana V. Kuzmicheva, Asiiat I. Tekeeva, James D. Kolokolov, Mikhail V. Volkonskii, Irina V. Poddubnaya
Publicado 2020

Prediction of survival after eribulin chemotherapy for breast cancer by absolute lymphocyte counts and progression types

por Tamami Morisaki, Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, Koji Takada, Sae Ishihara, Masatsune Shibutani, Hiroaki Tanaka, Kosei Hirakawa, Masaichi Ohira
Publicado 2021

Eribulin activity in soft tissue sarcoma monolayer and three-dimensional cell line models: could the combination with other drugs improve its antitumoral effect?

por Javier Escudero, Victoria Heredia-Soto, Yinyin Wang, Patricia Ruiz, Yingying Hu, Alejandro Gallego, Jose Juan Pozo-Kreilinger, Virginia Martinez-Marin, Alberto Berjon, Eduardo Ortiz-Cruz, Daniel Bernabeu, Jaime Feliu, Jing Tang, Andres Redondo, Marta Mendiola
Publicado 2021